Abstract BACKGROUND: The recurrence of hepatitis C viral infection is common after liver transplant, and achieving a sustained virological response to antiviral treatment is desirable for reducing the risk of graft loss and improving patients' survival. AIM: To investigate the long-term maintenance of sustained virological response in liver transplant recipients with hepatitis C recurrence. METHODS: 436 Liver transplant recipients (74.1% genotype 1) who underwent combined antiviral therapy for hepatitis C recurrence were retrospectively evaluated. RESULTS: The overall sustained virological response rate was 40% (173/436 patients), and the mean follow-up after liver transplantation was 11±3.5 years (range, 5-24). Patients with a sustained virological response demonstrated a 5-year survival rate of 97% and a 10-year survival rate of 93%; all but 6 (3%) patients remained hepatitis C virus RNA-negative during follow-up. Genotype non-1 (p=0.007), treatment duration >80% of the scheduled period (p=0.027), and early virological response (p=0.002), were associated with the maintenance of sustained virological response as indicated by univariate analysis. Early virological response was the only independent predictor of sustained virological response maintenance (p=0.008). CONCLUSIONS: Sustained virological response achieved after combined antiviral treatment is maintained in liver transplant patients with recurrent hepatitis C and is associated with an excellent 5-year survival.

Background: The recurrence of hepatitis C viral infection is common after liver transplant, and achieving a sustained virological response to antiviral treatment is desirable for reducing the risk of graft loss and improving patients' survival. Aim: To investigate the long-term maintenance of sustained virological response in liver transplant recipients with hepatitis C recurrence. Methods: 436 Liver transplant recipients (74.1% genotype 1) who underwent combined antiviral therapy for hepatitis C recurrence were retrospectively evaluated. Results: The overall sustained virological response rate was 40% (173/436 patients), and the mean follow-up after liver transplantation was 11. ±. 3.5 years (range, 5-24). Patients with a sustained virological response demonstrated a 5-year survival rate of 97% and a 10-year survival rate of 93%; all but 6 (3%) patients remained hepatitis C virus RNA-negative during follow-up. Genotype non-1 (p= 0.007), treatment duration >80% of the scheduled period (p= 0.027), and early virological response (p= 0.002), were associated with the maintenance of sustained virological response as indicated by univariate analysis. Early virological response was the only independent predictor of sustained virological response maintenance (p= 0.008). Conclusions: Sustained virological response achieved after combined antiviral treatment is maintained in liver transplant patients with recurrent hepatitis C and is associated with an excellent 5-year survival. © 2014 Editrice Gastroenterologica Italiana S.r.l.

Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C / Ponziani, F. R.; Vigano, R.; Iemmolo, R. M.; Donato, M. F.; Rendina, M.; Toniutto, P.; Pasulo, L.; Morelli, M. C.; Burra, P.; Miglioresi, L.; Merli, M.; Di Paolo, D.; Fagiuoli, S.; Gasbarrini, A.; Pompili, M.; Belli, L.; Gerunda, G. E.; Marino, M.; Montalti, R.; Di Benedetto, F.; De Ruvo, N.; Rigamonti, C.; Colombo, M.; Rossi, G.; Di Leo, A.; Lupo, L.; Memeo, V.; Bringiotti, R.; Zappimbulso, M.; Bitetto, D.; Vero, V.; Colpani, M.; Fornasiere, E.; Pinna, A. D.; Morelli, M. C.; Bertuzzo, V.; De Martin, E.; Senzolo, M.; Ettorre, G. M.; Visco-Comandini, U.; Antonucci, G.; Angelico, M.; Tisone, G.; Giannelli, V.; Giusto, M.. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - STAMPA. - 46:5(2014), pp. 440-445. [10.1016/j.dld.2014.01.157]

Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C

Di Benedetto F.
Membro del Collaboration Group
;
2014

Abstract

Background: The recurrence of hepatitis C viral infection is common after liver transplant, and achieving a sustained virological response to antiviral treatment is desirable for reducing the risk of graft loss and improving patients' survival. Aim: To investigate the long-term maintenance of sustained virological response in liver transplant recipients with hepatitis C recurrence. Methods: 436 Liver transplant recipients (74.1% genotype 1) who underwent combined antiviral therapy for hepatitis C recurrence were retrospectively evaluated. Results: The overall sustained virological response rate was 40% (173/436 patients), and the mean follow-up after liver transplantation was 11. ±. 3.5 years (range, 5-24). Patients with a sustained virological response demonstrated a 5-year survival rate of 97% and a 10-year survival rate of 93%; all but 6 (3%) patients remained hepatitis C virus RNA-negative during follow-up. Genotype non-1 (p= 0.007), treatment duration >80% of the scheduled period (p= 0.027), and early virological response (p= 0.002), were associated with the maintenance of sustained virological response as indicated by univariate analysis. Early virological response was the only independent predictor of sustained virological response maintenance (p= 0.008). Conclusions: Sustained virological response achieved after combined antiviral treatment is maintained in liver transplant patients with recurrent hepatitis C and is associated with an excellent 5-year survival. © 2014 Editrice Gastroenterologica Italiana S.r.l.
2014
46
5
440
445
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C / Ponziani, F. R.; Vigano, R.; Iemmolo, R. M.; Donato, M. F.; Rendina, M.; Toniutto, P.; Pasulo, L.; Morelli, M. C.; Burra, P.; Miglioresi, L.; Merli, M.; Di Paolo, D.; Fagiuoli, S.; Gasbarrini, A.; Pompili, M.; Belli, L.; Gerunda, G. E.; Marino, M.; Montalti, R.; Di Benedetto, F.; De Ruvo, N.; Rigamonti, C.; Colombo, M.; Rossi, G.; Di Leo, A.; Lupo, L.; Memeo, V.; Bringiotti, R.; Zappimbulso, M.; Bitetto, D.; Vero, V.; Colpani, M.; Fornasiere, E.; Pinna, A. D.; Morelli, M. C.; Bertuzzo, V.; De Martin, E.; Senzolo, M.; Ettorre, G. M.; Visco-Comandini, U.; Antonucci, G.; Angelico, M.; Tisone, G.; Giannelli, V.; Giusto, M.. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - STAMPA. - 46:5(2014), pp. 440-445. [10.1016/j.dld.2014.01.157]
Ponziani, F. R.; Vigano, R.; Iemmolo, R. M.; Donato, M. F.; Rendina, M.; Toniutto, P.; Pasulo, L.; Morelli, M. C.; Burra, P.; Miglioresi, L.; Merli, M.; Di Paolo, D.; Fagiuoli, S.; Gasbarrini, A.; Pompili, M.; Belli, L.; Gerunda, G. E.; Marino, M.; Montalti, R.; Di Benedetto, F.; De Ruvo, N.; Rigamonti, C.; Colombo, M.; Rossi, G.; Di Leo, A.; Lupo, L.; Memeo, V.; Bringiotti, R.; Zappimbulso, M.; Bitetto, D.; Vero, V.; Colpani, M.; Fornasiere, E.; Pinna, A. D.; Morelli, M. C.; Bertuzzo, V.; De Martin, E.; Senzolo, M.; Ettorre, G. M.; Visco-Comandini, U.; Antonucci, G.; Angelico, M.; Tisone, G.; Giannelli, V.; Giusto, M.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1249418
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact